The current first-line treatment for esophagogastric junction adenocarcinoma without HER-2 overexpression or microsatellite instability is a combination of chemotherapy and immunotherapy.(11–14) In Brazil, the use of nivolumab is independent of PD-L1 expression.(15). Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.